EPIFOAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPIFOAM (EPIFOAM).
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
| Metabolism | Metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). |
| Excretion | Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine. |
| Half-life | 2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect. |
| Protein binding | 95-98% bound, primarily to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | 0.3-0.6 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding and confinement to intravascular space. |
| Bioavailability | Topical: minimal systemic absorption (<5%) due to local metabolism and high first-pass cutaneous clearance; intravenous: 100% (not applicable for standard foam formulation). |
| Onset of Action | Topical: within 30 minutes of application; intravenous: immediate (within 1-2 minutes) when used systemically. |
| Duration of Action | Topical: 4-6 hours following single application; intravenous: 1-2 hours for hemodynamic effects (if used off-label). |
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No adjustment required; minimal hepatic metabolism due to topical application. |
| Pediatric use | Not recommended for children under 12 years; safety and efficacy not established. |
| Geriatric use | No specific dosage adjustment; use as directed for adults, with caution for skin integrity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPIFOAM (EPIFOAM).
| Breastfeeding | Small amounts of topical hydrocortisone may be absorbed. M/P ratio not available. Considered compatible with breastfeeding if used sparingly on small areas. Avoid application to breast prior to nursing. |
| Teratogenic Risk | Epifoam contains pramoxine and hydrocortisone. Systemic absorption of hydrocortisone is minimal with topical use; however, chronic high-dose use may be associated with intrauterine growth restriction and adrenal suppression in neonates. No definitive teratogenic risk identified in first trimester. Risk in second and third trimesters is low with typical use. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to epinephrine or any component of the formulation","Use in patients with closed-angle glaucoma (if systemic), during general anesthesia with halogenated hydrocarbons or cyclopropane","Use in patients with coronary insufficiency or cardiac arrhythmias (relative)"]
| Precautions | ["May cause hypertension, tachycardia, arrhythmias, and myocardial ischemia, especially in patients with cardiovascular disease","Use with caution in patients with hyperthyroidism, diabetes mellitus, pheochromocytoma, or narrow-angle glaucoma","Avoid extravasation as it may cause tissue necrosis"] |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required for maternal use; monitor for systemic corticosteroid effects if used extensively. Fetal monitoring only indicated if prolonged high-dose usage occurs (e.g., for growth restriction or adrenal suppression). |
| Fertility Effects | No known effects on fertility with topical use. |